Tenpoint Therapeutics Strengthens Leadership Team with Appointment of Melissa Epperly as CFO

Tenpoint Therapeutics, a clinical-stage biotechnology company dedicated to developing treatments for vision rejuvenation in the aging eye, has announced the appointment of Melissa Epperly as its new Chief Financial Officer. Epperly's role will be crucial in steering the company's financial strategy and capital markets activities, especially as Tenpoint prepares for the anticipated U.S. launch of BRIMOCHOLPF, its leading candidate for treating presbyopia.

With over 20 years of financial leadership in the biopharmaceutical sector, Epperly's expertise is expected to be invaluable. Her previous tenure as CFO at Zentalis Pharmaceuticals, where she successfully navigated the company through an IPO and raised significant capital, highlights her capability to drive financial growth and stability. Tenpoint's CEO, Henric Bjarke, emphasized Epperly's deep capital markets experience and operational command as key assets for the company's transition into a commercial-stage entity.

Epperly's appointment comes at a critical juncture for Tenpoint Therapeutics, as the company advances BRIMOCHOLPF through regulatory processes. This treatment aims to address presbyopia, a condition affecting approximately two billion people worldwide, by correcting the loss of near vision. The potential market impact of BRIMOCHOLPF, combined with Epperly's financial acumen, positions Tenpoint for significant growth and the opportunity to make a lasting impact on global eye health.